SCHEMBL503234

SCHEMBL503234

c1ccc(-c2c[nH]nn2)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.61
NPC1 O15118 8/20 0.61
RAB9A P51151 7/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
TP53 P04637 4/20 0.61
LMNA P02545 3/20 0.61
HTT P42858 3/20 0.61
ALOX15 P16050 3/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
PKM P14618 2/20 0.61
HSD17B10 Q99714 2/20 0.61
ALDH1A1 P00352 1/20 0.61
HPGD P15428 1/20 0.61
CCR1 P32246 3/20 0.58
CCR5 P51681 3/20 0.58
CCR8 P51685 3/20 0.58
CYP1A2 P05177 1/20 0.58
POLB P06746 1/20 0.58
METAP1 P53582 1/20 0.58
BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28352665 0.94 KDM4E (0.55) KDM4ENPC1RAB9ASMN1; SMN2TP53
Pyridine SCHEMBL27602451 0.93 KDM4E (0.53) KDM4ENPC1RAB9ASMN1; SMN2TP53
Urea SCHEMBL7991617 0.89 KDM4E (0.50) KDM4ENPC1RAB9ASMN1; SMN2TP53
Dipyridyl SCHEMBL1699769 0.79 KDM4E (0.93) KDM4ENPC1RAB9ASMN1; SMN2TP53
Dipyridyl SCHEMBL29601520 0.79 KDM4E (0.93) KDM4ENPC1RAB9ASMN1; SMN2TP53
Dipyridyl SCHEMBL143849 0.79 KDM4E (0.93) KDM4ENPC1RAB9ASMN1; SMN2TP53
Dipyridyl SCHEMBL1960478 0.79 KDM4E (0.93) KDM4ENPC1RAB9ASMN1; SMN2TP53
SCHEMBL1456153 0.77 KDM4E (1.00) KDM4ENPC1RAB9ASMN1; SMN2TP53
SCHEMBL1456985 0.77 KDM4E (1.00) KDM4ENPC1RAB9ASMN1; SMN2TP53
SCHEMBL30211369 0.77 KDM4E (1.00) KDM4ENPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025217208-A1 CHEMICAL MECHANICAL PLANARIZATION POLISHING FOR INTERCONNECTS DIFFUSION BARRIER MATERIALS VERSUM MATERIALS US, LLC (US) 2025-10-16 WO claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
EP-4463230-A1 HALF-SANDWICH TRANSITION METAL COMPLEXES AND USES THEREOF Debreceni Egyetem (HU) 2024-11-20 EP claimed
US-20240082433-A1 TUMOR RESECTION PROCESS AND COMPOSITION CONTAINING IRIDIUM-CONTAINING NUCLEOSIDE CLEVELAND STATE UNIVERSITY (US) 2024-03-14 US claimed
CN-116425791-A Photochromic germanium-doped cyclopentadiene condensed diaryl ethylene and preparation thereof 香港大学 2023-07-14 CN claimed
WO-2023041947-A1 HALF-SANDWICH TRANSITION METAL COMPLEXES AND USES THEREOF DEBRECENI EGYETEM (HU) 2023-03-23 WO claimed
CN-111085267-B Polymer-loaded Cu/TEMPO catalyst and preparation method and application thereof 湖北大学 2022-11-25 CN claimed
US-11357708-B2 Dental composites with improved storage stability IVOCLAR VIVADENT AG (LI) 2022-06-14 US claimed
EP-3042645-B1 Dental composites with improved storage stability IVOCLAR VIVADENT AG (LI) 2022-04-27 EP claimed
US-20210206791-A1 SELECTIVE METAL-MEDIATED ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2021-07-08 US claimed
EP-1434772-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2005-05-04 EP claimed
US-20040192914-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2004-09-30 US claimed
EP-1434772-A1 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2004-07-07 EP claimed
US-20030220371-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2003-11-27 US claimed
EP-1274424-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2003-09-17 EP claimed
WO-2003031434-A1 COMPOUNDS AND METHODS SMITH KLINE BEECHAM CORPORATION (US) 2003-04-17 WO claimed
EP-1274424-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-15 EP claimed
WO-2001078723-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2001-10-25 WO claimed
EP-0150419-B1 2H-v-triazolyl[4,5-b]pyridines and their use BASF Aktiengesellschaft (DE) 1988-07-27 EP claimed
EP-0150419-A1 2H-v-triazolyl[4,5-b]pyridines and their use BASF Aktiengesellschaft (DE) 1985-08-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192914-A1 Compounds and methods METAP2, METAP1, DNPEP KDM4E 1697/4885NPC1 3027/4885RAB9A 906/4885
US-20240082433-A1 TUMOR RESECTION PROCESS AND COMPOSITION CONTAINING IRIDIUM-CONTAINING NUCLEOSIDE IMPDH1, TYMP, IMPDH2 KDM4E 3329/4885NPC1 1823/4885RAB9A 936/4885
US-20030220371-A1 Compounds and methods METAP2, METAP1, DNPEP KDM4E 1351/4885NPC1 2301/4885RAB9A 1701/4885
US-20210206791-A1 SELECTIVE METAL-MEDIATED ARYLATION OF DICHALCOGENIDES IN BIOMOLECULES SCLY, SELENOI, PTMS KDM4E 4707/4885NPC1 4066/4885RAB9A 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.